Celiprolol
CARDIOVASCULAR SYSTEM
Also known as: celiprolol HCl, celiprolol hydrochloride, celiprolol monohydrochloride, DL-Celiprolol, selectol
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Celiprolol is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1982. DrugCentral lists 3 molecular targets, including ADRB1, ADRB2 and Htr1a. Recorded indications include Angina pectoris and Hypertensive disorder.
- Molecular targets: ADRB1, ADRB2 and Htr1a (3 listed in DrugCentral).
- Indications: Angina pectoris and Hypertensive disorder.
- ATC code: C07AB08 (Beta blocking agents, selective).
- Molecular formula: C20H33N3O4; molecular weight 379.50 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Angina pectoris
- Hypertensive disorder
Mechanism & targets
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Beta-1 adrenergic receptor | ADRB1 | antagonist | Ki 8.10 |
| Beta-2 adrenergic receptor | ADRB2 | agonist | Ki 6.80 |
| 5-hydroxytryptamine receptor 1A | Htr1a | unknown | Ki 5.05 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1982-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C07AB08 | CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, selective |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Nipple inflammation | 92.1 |
| Bradycardia | 87.6 |
| Acute kidney injury | 83.0 |
| Nipple disorder | 67.0 |
| Interstitial lung disease | 54.3 |
| Prevertebral soft tissue swelling of cervical space | 49.6 |
| Hyponatraemia | 49.3 |
| Atrioventricular block complete | 47.2 |
| Hepatocellular injury | 46.0 |
| Eosinophilia | 45.9 |
| Pemphigoid | 43.6 |
| Hypotension | 38.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Celiprolol is on its molecule page.
| Molecular formula | C20H33N3O4 |
|---|---|
| Molecular weight | 379.50 g/mol |
| CAS number | 56980-93-9 |
| InChIKey | JOATXPAWOHTVSZ-UHFFFAOYSA-N |
| PubChem CID | 2663 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Celiprolol used for?
DrugCentral lists the following indications for Celiprolol: Angina pectoris and Hypertensive disorder.
How does Celiprolol work?
Its molecular targets in DrugCentral include ADRB1 (antagonist), ADRB2 (agonist) and Htr1a.
When was Celiprolol first approved?
Celiprolol was first approved by the YEAR INTRODUCED in 1982.
What is the chemical formula of Celiprolol?
Celiprolol has the molecular formula C20H33N3O4 and a molecular weight of 379.50 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 569 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1742424 — compound record and bioactivity
- PubChem CID 2663 — chemical identifiers
- DrugBank DB04846 — drug record
- FDA UNII DRB57K47QC — substance identity
- UniProt P08588 (ADRB1) — target protein
- UniProt P07550 (ADRB2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.